To CRISPR or Not to CRISPR, That Is the Question: IP, Technical Issues, & the 3Rs


Wednesday, April 3, 2019
10:00 AM - 11:00 AM EDT/4:00 PM - 5:00 PM CEST


Online Webinar
digital dna double helix genetic engineering


The use of CRISPR/Cas9* genome editing for the creation of unique rodent models of human disease has revolutionized the field - but every revolution raises challenging issues.

Join our presentation as we review the latest considerations for the technology as it applies to in vivo research and answer key questions including:

  • CRISPR/Cas9 IP/license constraints: how does it impact your project?
  • Is it compatible with the goals of the 3Rs?
  • Does CRISPR allow for the generation of relevant models?


  • Jean Cozzi, PhD, Innovation Manager, Charles River

*CRISPR/CAS9 used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.

Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.